A detailed history of Brown, Lisle/Cummings, Inc. transactions in Organon & Co. stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 8,693 shares of OGN stock, worth $163,254. This represents 0.05% of its overall portfolio holdings.

Number of Shares
8,693
Previous 10,322 15.78%
Holding current value
$163,254
Previous $214 Million 22.17%
% of portfolio
0.05%
Previous 0.07%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$18.65 - $23.03 $30,380 - $37,515
-1,629 Reduced 15.78%
8,693 $166 Million
Q2 2024

Jul 17, 2024

SELL
$17.45 - $21.96 $40,082 - $50,442
-2,297 Reduced 18.2%
10,322 $214 Million
Q1 2024

Jun 28, 2024

SELL
$13.78 - $18.8 $27,601 - $37,656
-2,003 Reduced 13.7%
12,619 $237 Million
Q4 2023

Jun 28, 2024

SELL
$10.95 - $17.32 $91,016 - $143,963
-8,312 Reduced 36.24%
14,622 $211 Million
Q3 2023

Jun 28, 2024

SELL
$16.59 - $23.77 $18,497 - $26,503
-1,115 Reduced 4.64%
22,934 $398 Million
Q2 2023

Jun 28, 2024

SELL
$19.27 - $24.63 $49,504 - $63,274
-2,569 Reduced 9.65%
24,049 $500 Million
Q1 2023

Jun 28, 2024

SELL
$21.42 - $32.08 $23,369 - $34,999
-1,091 Reduced 3.94%
26,618 $626 Million
Q4 2022

Jun 28, 2024

SELL
$23.31 - $28.61 $12,424 - $15,249
-533 Reduced 1.89%
27,709 $774 Million
Q2 2022

Jun 28, 2024

BUY
$31.66 - $38.9 $50,054 - $61,500
1,581 Added 5.93%
28,242 $953 Million
Q1 2022

Jun 28, 2024

BUY
$30.45 - $39.36 $92,415 - $119,457
3,035 Added 12.85%
26,661 $931 Million
Q4 2021

Jun 28, 2024

BUY
$28.67 - $37.13 $677,357 - $877,233
23,626 New
23,626 $719 Million

Others Institutions Holding OGN

About Organon & Co.


  • Ticker OGN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 254,330,000
  • Market Cap $4.78B
  • Description
  • Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...
More about OGN
Track This Portfolio

Track Brown, Lisle/Cummings, Inc. Portfolio

Follow Brown, Lisle/Cummings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown, Lisle/Cummings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Brown, Lisle/Cummings, Inc. with notifications on news.